

D Alan Anthony

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/332899/publications.pdf>

Version: 2024-02-01

22
papers

5,919
citations

687363

13
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

7939
citing authors

#	ARTICLE	IF	CITATIONS
1	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1273-1281.	27.0	3,370
2	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet</i> , The, 2017, 389, 1011-1024.	13.7	1,475
3	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	288
4	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 520-529.	4.2	189
5	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2019, 154, 1038.	4.3	154
6	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017, 87, 147-163.	2.8	108
7	A phase I trial of the \hat{I}^3 -secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2018, 118, 793-801.	6.4	90
8	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	1.6	65
9	First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5908-5917.	7.0	38
10	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , 2018, 118, 947-954.	6.4	30
11	Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. <i>Cancer Immunology Research</i> , 2022, 10, 745-756.	3.4	22
12	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4516-4516.	1.6	20
13	A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3095-3095.	1.6	18
14	â€Tablet burdenâ€™ in patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2016, 55, 1-6.	2.8	12
15	Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth. <i>Frontiers in Oncology</i> , 2020, 10, 575148.	2.8	9
16	Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies. , 2022, 233, 108028.		8
17	Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. <i>BMC Cancer</i> , 2012, 12, 536.	2.6	7
18	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. <i>Cancers</i> , 2021, 13, 5758.	3.7	5

#	ARTICLE	IF	CITATIONS
19	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. <i>Acta Oncologica</i> , 2022, 61, 583-590.	1.8	4
20	Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. <i>BMC Cancer</i> , 2016, 16, 779.	2.6	3
21	A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. <i>British Journal of Cancer</i> , 2019, 120, 579-586.	6.4	2
22	Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	1.3	2